Presentation Will Provide Update on
Survival Trends in Various Population Subgroups
Medicenna to also Present at the LD Micro Investor
Conference
TORONTO and HOUSTON, Dec. 9,
2019 /PRNewswire/ - Medicenna Therapeutics Corp.
("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a
clinical stage immuno-oncology company, today announced that it
will present results from the Phase 2b clinical trial of MDNA55 for the treatment of
recurrent glioblastoma (rGBM) at the Inaugural Glioblastoma Drug
Development Annual Summit to be held on December 10 and 11 at the Westin Boston
Waterfront Hotel in Boston,
Massachusetts.
The oral presentation will provide details on survival seen in
patients with rGBM from the MDNA55 Phase 2b clinical trial, including trends observed in
different population subgroups.
The details of the presentation are as follows:
|
Title:
|
Clinical Case Study:
Using a Multi-pronged Approach to Treating Recurrent GBM
|
|
- Overcoming the
Tumor and its Microenvironment
|
|
Presenter:
|
Dr. Fahar Merchant,
PhD, President and CEO of Medicenna Therapeutics
|
|
Date/Time:
|
Wednesday, December
11, 2019 at 10:30 AM ET
|
|
Location:
|
Westin Boston
Waterfront Hotel, 425 Summer Street, Boston
|
In addition, Medicenna will be presenting at the
12th Annual LD Micro Main Event Investor Conference taking
place at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Ms. Elizabeth Williams, Medicenna's CFO is scheduled
to present on Tuesday, December 10,
2019 at 3:20 p.m. Pacific Time
and will be available for one-on-one meetings on December 10th and 11th.
About Medicenna Therapeutics Corp.
Medicenna is a
clinical stage immunotherapy company focused on oncology and the
development and commercialization of novel, highly selective
versions of IL-2, IL-4 and IL-13 Superkines and first in class
Empowered Cytokines™ (ECs) for the treatment of a broad range of
cancers. Supported by a US$14.1M
non-dilutive grant from CPRIT (Cancer Prevention and Research
Institute of Texas), Medicenna's
lead IL4-EC, MDNA55, has completed enrolling patients in a Phase
2b clinical trial for rGBM, the most
common and uniformly fatal form of brain cancer, at top-ranked
brain cancer centres in the US. MDNA55 has been studied in five
clinical trials involving 132 patients, including 112 adults with
rGBM. MDNA55 has demonstrated compelling efficacy and has obtained
Fast-Track and Orphan Drug status from the FDA and FDA/EMA
respectively. For more information, please visit
www.medicenna.com.
View original
content:http://www.prnewswire.com/news-releases/medicenna-announces-presentation-of-the-mdna55-clinical-trial-at-the-inaugural-glioblastoma-drug-development-annual-summit-300971303.html
SOURCE Medicenna Therapeutics Corp.